Cellular immunotherapies enable the patient’s immune system to eliminate cancer cells. To implement this process, our team modifies the patient’s immune cells with T-cell receptors (TCR) or chimeric antigen receptors (CAR) that recognize tumor cells. We then re-infuse those cells into the patient’s body where they work as ‘living drugs.’
Within the Collaborative Research Centre/Transregio (CRC/TRR) 221 innovative immune modulation strategies will be investigated to separate GvHD from GvL effects in order to enhance the safety and efficacy of allo-HSCT in the future.
